Back

Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48

31 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation in ‘Special’ Situations Oral Anticoagulation ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Jan Steffel

Klinik Hirslanden, Zurich (Switzerland)

7 More presentations in this session

Presentation thumbnail
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with antiphospholipid syndrome: a nationwide cohort study
Assistant Professor P. Yang (Seongnam, KR)
Abstract Slides Video
Presentation thumbnail
Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study
Doctor M. Proietti (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Reduced stroke risk without increased bleeding risk in patients with atrial fibrillation and complicated liver cirrhosis treated with oral anticoagulation
Doctor K. Steensig (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS)
Doctor T. Chao (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation in ‘Special’ Situations

The Event

Event poster

ESC Congress 2020

31 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources